Loading…
Aspire Biopharma Holdings, Inc. is projected to decline to $5.94 by 2027, a -1% move from its current price of $6.01. ASBP is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $5.54 | $6.01 | $6.53 | +0.03% |
| Jul 14 | $5.36 | $6.01 | $6.75 | +0.07% |
| Jul 15 | $5.22 | $6.02 | $6.93 | +0.10% |
| Jul 16 | $5.11 | $6.02 | $7.09 | +0.13% |
| Jul 17 | $5.01 | $6.02 | $7.23 | +0.16% |
| Jul 18 | $4.93 | $6.02 | $7.36 | +0.20% |
| Jul 19 | $4.85 | $6.02 | $7.48 | +0.23% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.85 | $6.02 | $7.48 | +0.23% |
| Week 2 | $4.44 | $6.04 | $8.21 | +0.46% |
| Week 3 | $4.16 | $6.05 | $8.81 | +0.69% |
| Week 4 | $3.93 | $6.07 | $9.36 | +0.92% |
| Week 5 | $3.74 | $6.08 | $9.87 | +1.15% |
| Week 6 | $3.58 | $6.09 | $10.37 | +1.38% |
| Week 7 | $3.44 | $6.11 | $10.84 | +1.61% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company that develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers a soluble, pH neutral, fast acting sublingual aspirin product that addresses cardiology emergencies and pain management.
The company is developing sublingually administered formulations for products such as melatonin sleep-aid; vitamins D, E, and K; testosterone; and semaglutide, along with anti-nausea products, anti-psychotic products, ED drugs, seizure medications, and other drug classes, including caffeine products like a single dose sublingual pre-workout supplement.
Aspire Biopharma Holdings, Inc. was founded in 2021 and is headquartered in Estero, Florida.
Aspire Biopharma Holdings, Inc. (ASBP) operates in the Healthcare sector as an early-stage biopharmaceutical company focused on sublingual delivery technology.
The stock is currently priced at $6.07 with a market capitalization of $7.86M, and its market rank stands at 5200.
The near-term technical picture shows a neutral to muted path with a 30-day range from $3.48 to $10.60, a sentiment reading of NEUTRAL, and a RSI of 50. The stock’s momentum indicators show a SMA50 of $4.82 and a SMA200 of $4.98, with a near-term support of $4.67 and resistance at $6.65.
The forecast implies a mixed price outlook across years, with 2026 averaging $6.07 and 2030 averaging $5.15, then moving higher later to $10.79 by 2040 and $14.35 by 2050, reflecting upside potential amid notable volatility.
A major floor 97.4% below — a decisive break under it would weaken the trend.
The nearest floor, 17.5% below — buyers have tended to step in here.
The nearest ceiling, 10.6% above — a clean break opens room to run.
A major ceiling 25.8% above — clearing it would confirm fresh momentum.
Key ASBP support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ASBP market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.87 | Buy | $5.94 | Buy |
| MA 10 | $5.89 | Buy | $5.95 | Buy |
| MA 20 | $6.00 | Buy | $5.87 | Buy |
| MA 50 | $4.94 | Buy | $4.97 | Buy |
| MA 100 | $2.96 | Buy | $4.84 | Buy |
| MA 200 | $4.93 | Buy | $19.61 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.34 | Neutral |
| Stoch RSI (14) | 43.89 | Neutral |
| CCI (20) | 1.18 | Neutral |
| Williams %R (14) | -44.17 | Info |
| MACD (12,26,9) | -0.11 | Sell |
| ROC (12) | -2.59 | Sell |
| Bollinger %B (20,2) | 0.50 | Neutral |
| Stochastic %K (14) | 55.83 | Neutral |
| TRIX (15) | 0.87 | Buy |
| Awesome (5,34) | 0.01 | Buy |
| Ultimate (7,14,28) | 58.03 | Neutral |
| Momentum (10) | -0.44 | Sell |
| Aroon Osc (25) | -16.00 | Sell |
| Hull MA (9) | 5.91 | Buy |
| ADX (14) | 15.53 | Neutral |
| ATR (14) | 0.36 | Info |
The 30-day technical picture is neutral, with RSI14 at 50. The price action reflects a balance around short-term moving averages, as SMA50 sits at $4.82 and SMA200 at $4.98.
Near-term support is indicated at $4.67 and resistance at $6.65, framed by a 30-day range of $3.48 to $10.60. The stock exhibits high near-term volatility, with annualized volatility listed at 200%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.155 | $6.01 | $9.07 | 0% | Neutral | |
| $4.31 | $5.94 | $8.86 | -1% | Neutral | |
| $4.28 | $6.26 | $9.95 | +4% | Neutral | |
| $3.37 | $5.20 | $8.67 | -13% | Neutral | |
| $3.15 | $5.09 | $8.83 | -15% | Bearish | |
| $3.56 | $6.01 | $10.80 | 0% | Neutral | |
| $3.68 | $6.49 | $12.01 | +8% | Neutral | |
| $4.56 | $8.38 | $15.95 | +39% | Bullish | |
| $4.50 | $8.59 | $16.77 | +43% | Bullish | |
| $3.39 | $6.73 | $13.45 | +12% | Neutral | |
| $4.81 | $10.69 | $23.47 | +78% | Bullish | |
| $6.41 | $14.24 | $32.76 | +137% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.155 | $6.01 | $7.62 | +0.00% |
| August 2026 | $5.10 | $6.17 | $7.79 | +2.74% |
| September 2026 | $5.04 | $6.19 | $7.97 | +0.26% |
| October 2026 | $5.41 | $6.73 | $8.82 | +8.74% |
| November 2026 | $5.57 | $7.00 | $9.31 | +4.03% |
| December 2026 | $5.31 | $6.74 | $9.07 | -3.82% |
Click any year to see its month-by-month ASBP forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The ASBP price prediction for 2026 points to an average of $6.01 (low $0.155, high $9.07) — a potential gain of 0% on today's $6.01. A consolidation phase looks the most probable path here.
In 2027, ASBP is projected to trade between $4.31 and $8.86, averaging $5.94 — a potential decline of -1% from today's $6.01. That is -1% versus the projected 2026 average. Price action looks broadly range-bound.
Aspire Biopharma Holdings, Inc.'s 2028 outlook centres on $6.26, within a $4.28 to $9.95 range. That is up +5% on the projected 2027 average. That marks a +4% change versus current levels. A consolidation phase looks the most probable path here.
By 2029, ASBP could reach as high as $8.67, with a base case around $5.20 and support toward $3.37 — roughly -13% from $6.01. Price action looks broadly range-bound.
Expect ASBP to range from $3.15 to $8.83 through 2030. The $5.09 average target implies a -15% move from current prices. That is -2% versus the projected 2029 average. Expect choppier, lower action through this leg of the cycle.
The ASBP price prediction for 2031 points to an average of $6.01 (low $3.56, high $10.80) — a potential gain of 0% on today's $6.01. Price action looks broadly range-bound.
In 2032, ASBP is projected to trade between $3.68 and $12.01, averaging $6.49 — a potential gain of +8% from today's $6.01. That is up +8% on the projected 2031 average. A consolidation phase looks the most probable path here.
Aspire Biopharma Holdings, Inc.'s 2033 outlook centres on $8.38, within a $4.56 to $15.95 range. That is up +29% on the projected 2032 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2034, ASBP could reach as high as $16.77, with a base case around $8.59 and support toward $4.50 — roughly +43% from $6.01. Buyers look set to stay in control over this stretch.
Expect ASBP to range from $3.39 to $13.45 through 2035. The $6.73 average target implies a +12% move from current prices. That is -22% versus the projected 2034 average. Price action looks broadly range-bound.
The ASBP price prediction for 2040 points to an average of $10.69 (low $4.81, high $23.47) — a potential gain of +78% on today's $6.01. Buyers look set to stay in control over this stretch.
In 2050, ASBP is projected to trade between $6.41 and $32.76, averaging $14.24 — a potential gain of +137% from today's $6.01. That is up +33% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in ASBP today (≈ 166.389351 ASBP) could be worth
$2,370.13
+$1,370.13 (+137%) by 2050 · US Dollar
Based on the average projected ASBP price of $14.24 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ASBPwould be worth at today's price.
$1,000 invested in ASBP on Jul 10, 2025 (≈ 72.254334 ASBP) would be worth
$434.25
-$565.75 (-56.6%) today · 0.43× · US Dollar
Based on a ASBP entry price of $13.84 vs. today's $6.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.21 | $967.79 | -3.2% |
| 1 month ago | $5.61 | $1,071.3 | +7.1% |
| 3 months ago | $1.06 | $5,669.81 | +467.0% |
| 6 months ago | $3.8 | $1,581.58 | +58.2% |
| 1 year ago | $13.84 | $434.25 | -56.6% |
| All time (4.2y) ago | $399.6 | $15.04 | -98.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ASBP forecast.
Our base-case forecast reaches $12.00 around 2050.
Implied market cap at $12.00: $15.54M
The multi-year forecast shows a path of mixed performance with alternating periods of consolidation and upside. In 2026 the average price is $6.07 with a 0% ROI, while 2027 shows $6.02 (−0.9% ROI) and 2028 at $6.32 (4.1% ROI). Downside pressure appears in 2029 at $5.25 average and 2029 with −13.6% ROI, followed by 2030 at $5.15 average with −15.1% ROI and bearish sentiment.
From 2031 onward the forecast turns more constructive; 2033 reaches an average of $8.50 with a 40% ROI and 2034 at $8.66 with a 42.7% ROI, both labeled bullish. The trajectory strengthens toward 2040, where the average price is $10.79 and ROI is 77.8% with bullish sentiment, and continues to 2050 with an average of $14.35 and ROI of 136.5% under bullish conditions.
Overall, the long horizon shows meaningful upside potential by the mid-to-late 2030s into 2040 and beyond, but with notable risk years such as 2029 and 2030 offering negative ROI and bearish signals.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $5.15 with a max of $8.95 and a min of $3.19, and a −15.1% ROI with a bearish sentiment.
Yes. The 2040 forecast lists an average price of $10.79, with a max of $23.69 and a min of $4.86, and a bullish sentiment with a 77.8% ROI.
The forecast is mixed. It includes neutral years (e.g., 2026–2031 with small or negative ROIs) and bullish years (2033–2034, 2040, 2050) with higher ROIs (40.0%, 42.7%, 77.8%, 136.5%), indicating potential upside but with clear downside risk in some periods.
The current price is $6.07 and the market capitalization is $7.86M.
The 2050 forecast shows a max price of $33.01 with an average of $14.35 and a ROI of 136.5%, under bullish sentiment.
Aspire Biopharma Holdings, Inc. Community Discussion
0Share your Aspire Biopharma Holdings, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.